XML 33 R20.htm IDEA: XBRL DOCUMENT
v3.23.1

Research and Development Costs (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2023
Research and Development [Abstract] |
Schedule of Research and Development Costs | Research and development costs, including costs associated with clinical trials involving the Company’s lead clinical compound LB-100, are summarized below based on the respective geographical regions where such costs are incurred. Schedule of Research and Development Costs
|  | 2023 |  |  | 2022 |
|  | Three Months Ended March 31, |
|  | 2023 |  |  | 2022 |
United States |  | $ | 135,907 |  |  | $ | 74,531 |
Spain |  |  | 975 |  |  |  | 328,829 |
China |  |  | — |  |  |  | 860 |
Netherlands |  |  | 52,203 |  |  |  | 54,230 |
Total |  | $ | 189,085 |  |  | $ | 458,450 |
Research and development expense |  | $ | 189,085 |  |  | $ | 458,450 |

X
- Definition Research Development [TableTextBlock] + References No definition available. + Details
Name: | LIXT_ResearchDevelopmentTableTextBlock
Namespace Prefix: | LIXT_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration